Function and Comorbidities of Apolipoprotein E in Alzheimer′s Disease
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Alzheimer′s disease (AD)—the most common type of dementia among the elderly—represents one of the most challenging and urgent medical mysteries affecting our aging population. Although dominant inherited mutation in genes involved in the amyloid metabolism can elicit familial AD, the overwhelming majority of AD cases, dubbed sporadic AD, do not display this Mendelian inheritance pattern. Apolipoprotein E (APOE), the main lipid carrier protein in the central nervous system, is the only gene that has been robustly and consistently associated with AD risk. The purpose of the current paper is thus to highlight the pleiotropic roles and the structure‐function relationship of APOE to stimulate both the functional characterization and the identification of novel lipid homeostasis‐related molecular targets involved in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“In contrast, the APOE2 variant is associated with a marked risk reduction of AD [7].”
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“APOE is the primary apolipoprotein in the CNS followed by APOJ (also known as Clusterin) [109], which has also been identified as a genetic risk factor in AD by genome-wide association approaches [17, 106, 110].”
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“While CNS neurons produce just enough cholesterol to survive and grow inefficient synapses [166], a glia-derived factor consisting of cholesterol complexed to APOE-containing lipoproteins strongly promotes synapse formation [107, 167].”
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 3×
“Because the possible roles of APOE in amyloid metabolism have been extensively reviewed recently by Kim and colleagues [106], only the potential role of APOE lipoproteins as scavengers of soluble beta amyloid (Aβ) peptides will be discussed in this section [21].”
The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M., Orsó, E., Klucken, J., Langmann, T., Böttcher, A., Diederich, W., Drobnik, W., Barlage, S., Büchler, C., Porsch-Özcürümez, M., et al. (1999) · Nature Genetics · doi:10.1038/11914 · Cited by 1,512
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367 · cited 1×
“While they remain controversial, a trend toward a decrease in AD risk is observed in populationbased studies with long-term use of NSAIDs, suggesting an early role of inflammation in AD [160, 162].”
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233 · cited 1×
“However, given the alarming aging of the population and the increase longevity of humans, Alzheimer’s disease (AD) and other related dementias are set to become the next great health crusade of the coming decades [1].”
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, C. R., Petersen, R. C., Xu, Y. C., Waring, S. C., O'Brien, P. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., & Kokmen, E. (1997) · Neurology · doi:10.1212/wnl.49.3.786 · Cited by 1,128
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108 · cited 3×
“Indeed, in addition to numerous case control studies [5, 6, 12] several independent genome-wide association studies (GWASs) have been performed in homogeneous and heterogeneous population of AD and age-matched control cases in North America, Europe, and Asia [13–17].”
Self-citationApolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions
William Rebeck, G., Reiter, J. S., Strickland, D. K., & Hyman, B. T. (1993) · Neuron · doi:10.1016/0896-6273(93)90070-8 · Cited by 1,107 · cited 1×
“Indeed, in addition to numerous case control studies [5, 6, 12] several independent genome-wide association studies (GWASs) have been performed in homogeneous and heterogeneous population of AD and age-matched control cases in North America, Europe, and Asia [13–17].”
Microglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Boyles, J. K., Pitas, R. E., Wilson, E., Mahley, R. W., & Taylor, J. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112130 · Cited by 829 · cited 1×
“oligodendrocytes, and ependymal cells synthesized APOE [86, 88].”
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796 · cited 1×
“APOE4 has smaller effects on the risk of cardiovascular disease than on AD, in the range of 10% to 50%, with effects peaking during middle age [130].”
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Three-Dimensional Structure of the LDL Receptor-Binding Domain of Human Apolipoprotein E
Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W., & Agard, D. A. (1991) · Science · doi:10.1126/science.2063194 · Cited by 678 · cited 2×
“protein is polymorphic, with three common isoforms bearing identical CT domain primary structure, but distinct NT domain sequence: at positions 112 and 158, E2 has cysteines, E4 has arginines, and E3 has a cysteine and an arginine, respectively [32, 56, 57] (Figure 1, Table 1).”
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673 · cited 1×
“For instance, while APOE3 and APOE4 bind to LDLR with similar affinities, the APOE2 isoform has less than 2% of the LDLR binding activity of APOE3, at least in peripheral cells [58, 59].”
de Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629
Self-citationApolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 7×
“Yet, molten-globulelike conformations are more prone to proteolysis, more vulnerable to degradation pathways and have been implicated in several diseases [44, 64].”
InfluentialIsoform-specific binding of apolipoprotein E to beta-amyloid.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31529-6 · Cited by 540
Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499 · cited 2×
“Indeed, in addition to numerous case control studies [5, 6, 12] several independent genome-wide association studies (GWASs) have been performed in homogeneous and heterogeneous population of AD and age-matched control cases in North America, Europe, and Asia [13–17].”
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · cited 1×
“While they remain controversial, a trend toward a decrease in AD risk is observed in populationbased studies with long-term use of NSAIDs, suggesting an early role of inflammation in AD [160, 162].”
GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Mahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421 · cited 1×
“This metabolite, only produced in neurons, is then directed to the liver where it can be excreted in the form of bile acids [126].”
Brecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G.-Q., Xu, Q., Dee Fish, J., Wyss-Coray, T., Buttini, M., Mucke, L., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4315-03.2004 · Cited by 403 · cited 3×
“The suboptimal features of APOE4 might also promote neurotoxicity and neuroinflammation through the proteolysis of APOE4 into putative neurotoxic NT and CT fragments, a process postulated to occur solely in neurons and not in astrocytes [77].”
InfluentialLynch, J. R., Tang, W., Wang, H., Vitek, M. P., Bennett, E. R., Sullivan, P. M., Warner, D. S., & Laskowitz, D. T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306923200 · Cited by 394 · cited 1×
“In vivo studies using human APOE knockin mice have shown that following lipopolysaccharide (LPS) administration, APOE4 mice have a greater neuroinflammatory response relative to the APOE3 mice, suggesting that APOE4 has a less effective anti-inflammatory effect [157].”
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385 · cited 1×
“As well, there is some debate as to whether the cholesterol transport pathway used by APOE and APOJ differs since the receptor for APOJ, megalin/LRP-2, is not expressed by neurons and APOJ levels which are significantly increased in AD brain [122, 123] are unaltered in ABCA1 knockout mice suggesting that APOJ does not…”
Microglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Holtzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · cited 1×
“More interestingly, cross-breeding of the humanized APOE4 or APOE3 mice with APP717 amyloid overexpressing transgenic mice almost completely prevented the characteristic accumulation of Aβ deposits reported in hippocampal and cortical areas [195].”
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 346 · cited 1×
“The lower stability of APOE4, its increased susceptibility for proteolysis as demonstrated by turnover studies in humans [73] and APOE human knockin mice [74] and its higher propensity to form molten-globule-like intermediates that actively bind to phospholipids and membranes could, in concert with fibrillar Aβ, promo…”
Abnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg, R. E., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112645 · Cited by 345
May, P. C., Lampert-Etchells, M., Johnson, S. A., Poirier, J., Masters, J. N., & Finch, C. E. (1990) · Neuron · doi:10.1016/0896-6273(90)90342-d · Cited by 339 · cited 1×
“As well, there is some debate as to whether the cholesterol transport pathway used by APOE and APOJ differs since the receptor for APOJ, megalin/LRP-2, is not expressed by neurons and APOJ levels which are significantly increased in AD brain [122, 123] are unaltered in ABCA1 knockout mice suggesting that APOJ does not…”
Self-citationDeletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease
Wahrle, S. E., Jiang, H., Parsadanian, M., Hartman, R. E., Bales, K. R., Paul, S. M., & Holtzman, D. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508780200 · Cited by 325 · cited 1×
“Consistent with this phenomenon, ABCA1 mouse knockouts exhibit poorly lipidated APOE which in turn has been shown to influence Aβ metabolism [111, 116].”
Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., & Agard, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31797-0 · Cited by 320
Human Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
Morrow, J. A., Segall, M. L., Lund-Katz, S., Phillips, M. C., Knapp, M., Rupp, B., & Weisgraber, K. H. (2000) · Biochemistry · doi:10.1021/bi000099m · Cited by 315 · cited 2×
“[66] J.”
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296 · cited 2×
“Indeed, in addition to numerous case control studies [5, 6, 12] several independent genome-wide association studies (GWASs) have been performed in homogeneous and heterogeneous population of AD and age-matched control cases in North America, Europe, and Asia [13–17].”
Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains.
Wetterau, J. R., Aggerbeck, L. P., Rall, S. C., & Weisgraber, K. H. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68778-2 · Cited by 293
The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.
Innerarity, T. L., Friedlander, E. J., Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44180-9 · Cited by 276 · cited 2×
“[35] T.”
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274
Nagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250 · cited 2×
“Indeed, carriers of the APOE2 allele have less AD pathological changes than APOE3 carriers, that is, less pathological Aβ, SP, and NFT levels [23–26], as well as larger regional cortical thicknesses and volumes indicative of greater brain reserve against cognitive decline [27].”
Wolk, D. A., Dickerson, B. C., Initiative, T. A. D. N., Weiner, M., Aiello, M., Aisen, P., Albert, M. S., Alexander, G., Anderson, H. S., Anderson, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001412107 · Cited by 248
Lalazar (1989) · doi:10.1016/s0021-9258(18)81806-3 · Cited by 238
Aggerbeck, L. P., Wetterau, J. R., Weisgraber, K. H., Wu, C. S., & Lindgren, F. T. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68779-4 · Cited by 229 · cited 1×
“The NT domain was shown to bear the LDLR binding site [28, 35–37], whereas residues within the lipid-binding CT domain mediate the lipoprotein binding [38–40] and the APOE self-association sites [31, 41, 42] (Table 1).”
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226 · cited 2×
“Indeed, carriers of the APOE2 allele have less AD pathological changes than APOE3 carriers, that is, less pathological Aβ, SP, and NFT levels [23–26], as well as larger regional cortical thicknesses and volumes indicative of greater brain reserve against cognitive decline [27].”
Fagan, A. M., Holtzman, D. M., Munson, G., Mathur, T., Schneider, D., Chang, L. K., Getz, G. S., Reardon, C. A., Lukens, J., Shah, J. A., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30001 · Cited by 222 · cited 3×
“Albeit their similar functions, APOE and APOJ are present on different HDL-like lipoprotein particles which differ in composition: APOJ-lipoprotein particles are lipid poor and have a higher phospholipid-tocholesterol ratio compared to APOE-lipoprotein particles [85, 119, 121].”
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.
Weisgraber, K. H., Innerarity, T. L., Harder, K. J., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44181-0 · Cited by 220 · cited 2×
“The NT domain was shown to bear the LDLR binding site [28, 35–37], whereas residues within the lipid-binding CT domain mediate the lipoprotein binding [38–40] and the APOE self-association sites [31, 41, 42] (Table 1).”
Lalazar, A., Weisgraber, K. H., Rall, S. C., Giladi, H., Innerarity, T. L., Levanon, A. Z., Boyles, J. K., Amit, B., Gorecki, M., & Mahley, R. W. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68957-4 · Cited by 209
Utermann, G., Pruin, N., & Steinmetz, A. (1979) · Clinical Genetics · doi:10.1111/j.1399-0004.1979.tb02028.x · Cited by 209
Genome-wide association study of CSF biomarkers Aβ 1-42 , t-tau, and p-tau 181p in the ADNI cohort
Kim, S., Swaminathan, S., Shen, L., Risacher, S. L., Nho, K., Foroud, T., Shaw, L. M., Trojanowski, J. Q., Potkin, S. G., Huentelman, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318204a397 · Cited by 206
Apolipoprotein E4 Forms a Molten Globule
Morrow, J. A., Hatters, D. M., Lu, B., Höchtl, P., Oberg, K. A., Rupp, B., & Weisgraber, K. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204898200 · Cited by 204
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Han, S.-H., Einstein, G., Weisgraber, K. H., Strittmatter, W. J., Saunders, A. M., Pericak-Vance, M., Roses, A. D., & Schmechel, D. E. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00013 · Cited by 195
Kim, W. S., Rahmanto, A. S., Kamili, A., Rye, K.-A., Guillemin, G. J., Gelissen, I. C., Jessup, W., Hill, A. F., & Garner, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607831200 · Cited by 191 · cited 1×
“It has been proposed that ABCA1 catalyses the initial transfer of cholesterol onto lipidpoor APOE and that ATP-binding cassette transporter G1 (ABCG1) finalizes the full lipidation of the apolipoprotein (Figure 2) [112, 113].”
DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., Sullivan, P. M., Fagan, A. M., Han, X., & Holtzman, D. M. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00049-3 · Cited by 180 · cited 1×
“Albeit their similar functions, APOE and APOJ are present on different HDL-like lipoprotein particles which differ in composition: APOJ-lipoprotein particles are lipid poor and have a higher phospholipid-tocholesterol ratio compared to APOE-lipoprotein particles [85, 119, 121].”
Ji, Z.-S., Miranda, R. D., Newhouse, Y. M., Weisgraber, K. H., Huang, Y., & Mahley, R. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112109200 · Cited by 177 · cited 1×
“The lower stability of APOE4, its increased susceptibility for proteolysis as demonstrated by turnover studies in humans [73] and APOE human knockin mice [74] and its higher propensity to form molten-globule-like intermediates that actively bind to phospholipids and membranes could, in concert with fibrillar Aβ, promo…”
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity
Guo, L., LaDu, M. J., & Van Eldik, L. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:205 · Cited by 175
Westerlund, J. A., & Weisgraber, K. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82318-3 · Cited by 164
Xie, C., Lund, E. G., Turley, S. D., Russell, D. W., & Dietschy, J. M. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300164-jlr200 · Cited by 159 · cited 1×
“Other pathways account for about 36% of the excretion; however, the mechanisms remain unclear and controversial [125, 127].”
Hartman, R. E., Wozniak, D. F., Nardi, A., Olney, J. W., Sartorius, L., & Holtzman, D. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7715 · Cited by 157
Liver X receptor activation restores memory in aged AD mice without reducing amyloid
Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V. W., van Vark-van der Zee, L. C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E. J. G., Steinbusch, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.005 · Cited by 154
Grootendorst, J., Bour, A., Vogel, E., Kelche, C., Sullivan, P. M., Dodart, J.-C., Bales, K., & Mathis, C. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.09.019 · Cited by 148 · cited 2×
“Interestingly, the introduction of human APOE3 or APOE4 in the APOE KO mice completely prevents the cognitive deficit typical of these APOE-deficient mice [189, 190].”
Apolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144 · cited 1×
“Age at onset appeared to be modulated by APOE genotype (earlier onset E4 > E3 > E2) [251, 252, 255, 256] and by sex [257].”
Bales, K. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00143-3 · Cited by 143
Beffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142 · cited 1×
“Interestingly, adult LDLR KO mice expressing no brain LDLR have a 50% reduction in APOE synthesis relative to wild-type mice [185], a feature not that dissimilar from the finding that APOE4/4 AD subjects express only 50% of the normal brain APOE levels of APOE3/3 individuals [72, 186].”
Self-citationFryer, J. D., DeMattos, R. B., McCormick, L. M., O'Dell, M. A., Spinner, M. L., Bales, K. R., Paul, S. M., Sullivan, P. M., Parsadanian, M., Bu, G., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502143200 · Cited by 139 · cited 1×
“Interestingly, adult LDLR KO mice expressing no brain LDLR have a 50% reduction in APOE synthesis relative to wild-type mice [185], a feature not that dissimilar from the finding that APOE4/4 AD subjects express only 50% of the normal brain APOE levels of APOE3/3 individuals [72, 186].”
Community Programs for the Prevention of Cardiovascular Disease: A Systematic Review
Pennant, M., Davenport, C., Bayliss, S., Greenheld, W., Marshall, T., & Hyde, C. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq171 · Cited by 131 · cited 3×
“Interestingly, these progressive degenerative disorders share common etiological grounds: advancing age, apolipoprotein (apo) E4 inheritance, cigarette smoking, high blood pressure, diabetes, obesity, oxidative stress, and abnormal blood cholesterol levels all concur to increase one’s liability to develop CVD [2, 3] a…”
Koldamova, R. P., Lefterov, I. M., Lefterova, M. I., & Lazo, J. S. (2001) · Biochemistry · doi:10.1021/bi002186k · Cited by 131 · cited 1×
“The functions of APOJ in lipid homeostasis and Aβ metabolism are very similar to those of APOE in that they are both carriers of cholesterol in the CNS and they both modulate amyloid fibrillogenesis and clearance [109, 119, 120].”
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Apolipoprotein E and Dementia in Parkinson Disease: A Meta-analysis
Huang, X., Chen, P., Kaufer, D. I., Tröster, A. I., & Poole, C. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.189 · Cited by 128
Reactivity of Apolipoprotein E4 and Amyloid β Peptide
Ji, Z.-S., Müllendorff, K., Cheng, I. H., Miranda, R. D., Huang, Y., & Mahley, R. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506646200 · Cited by 127
ApoE isoform affects LTP in human targeted replacement mice
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Ye, G. L., Sotak, M., Sullivan, P. M., Pasternak, J. F., & LaDu, M. J. (2004) · NeuroReport · doi:10.1097/00001756-200412030-00020 · Cited by 124
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00050-x · Cited by 118
Association of ALS with head injury, cigarette smoking and APOE genotypes
Schmidt, S., Kwee, L. C., Allen, K. D., & Oddone, E. Z. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.01.011 · Cited by 117
Lipid Binding-induced Conformational Change in Human Apolipoprotein E
Saito, H., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., Lund-Katz, S., & Phillips, M. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106337200 · Cited by 113 · cited 1×
“As suggested by the initial discovery that only lipidbound APOE binds to LDLR with high affinity [45], the structural organization of the APOE protein significantly changes when bound to lipids or lipoproteins [44, 46, 47].”
Reduced levels of human apoE4 protein in an animal model of cognitive impairment
Sullivan, P. M., Han, B., Liu, F., Mace, B. E., Ervin, J. F., Wu, S., Koger, D., Paul, S., & Bales, K. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.011 · Cited by 113
Apolipoprotein E Receptors Mediate the Effects of β-Amyloid on Astrocyte Cultures
LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., & Van Eldik, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000602200 · Cited by 103 · cited 1×
“Since the initial finding of decreased inflammation from glial Aβ-induced APOE production [145, 151], numerous studies have reported that APOE has an anti-inflammatory function and that its stimulation by Aβ acts as a negative feedback system [145, 151, 152].”
Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein.
Wilson, C., Mau, T., Weisgraber, K. H., Wardell, M. R., Mahley, R. W., & Agard, D. A. (1994) · Structure · doi:10.1016/s0969-2126(00)00072-1 · Cited by 100 · cited 2×
“This inhibition of the LDLR binding activity is mediated not only by the arginine-to-cysteine substitution at position 158, which disrupts the salt bridge network between residues R92, E96, R103, R150, D151, and D154 [33], but also by part of the CT domain [59] (Figure 1, Table 1).”
Mulder, M., Jansen, P. J., Janssen, B. J. A., van de Berg, W. D. J., van der Boom, H., Havekes, L. M., de Kloet, R. E., Ramaekers, F. C. S., & Blokland, A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.015 · Cited by 98 · cited 2×
“These mice exhibit progressive age-related memory loss and significant synaptic loss in the CA1 area (−35% at 11 months) of the hippocampus [184].”
Hippocampal atrophy rates and CSF biomarkers in elderly APOE 2 normal subjects
Chiang, G. C., Insel, P. S., Tosun, D., Schuff, N., Truran-Sacrey, D., Raptentsetsang, S. T., Jack, C. R., Aisen, P. S., Petersen, R. C., Weiner, M. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4d1 · Cited by 94 · cited 1×
“, higher CSF levels of Aβ (1–42), lower CSF p-tau and ttau concentrations) [217].”
Han, M.-R., Schellenberg, G. D., Wang, L.-S., & Initiative, T. A. D. N. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-90 · Cited by 93
Moulard, B., Sefiani, A., Laamri, A., Malafosse, A., & Camu, W. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(96)00085-8 · Cited by 93 · cited 1×
“Most striking results are the association with age at onset, with the APOE4 and APOE2 alleles, respectively, decreasing [270, 272] and increasing the age [270, 273], as well as the finding that APOE plasma levels (but not APOE genotype) were correlated with a faster rate of deterioration and shortened survival time [2…”
Mann, D. M. A., Iwatsubo, T., Pickering-Brown, S. M., Owen, F., Saido, T. C., & Perry, R. H. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13294-8 · Cited by 91 · cited 1×
“Accounting for as much as 50% of the genetic variation in liability to develop AD [18], carriers of the APOE4 allele who develop AD do so at an earlier age at onset and exhibit higher levels of soluble beta-amyloid (Aβ) peptide, increased senile plaque (SP) [19], and neurofibrillary tangle (NFT) accumulation, as well…”
Modulation of Apolipoprotein E Structure by Domain Interaction
Hatters, D. M., Budamagunta, M. S., Voss, J. C., & Weisgraber, K. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506044200 · Cited by 88
Why lipids are important for Alzheimer disease?
Hirsch-Reinshagen, V., Burgess, B. L., & Wellington, C. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0012-2 · Cited by 86
Acharya, P., Segall, M. L., Zaiou, M., Morrow, J., Weisgraber, K. H., Phillips, M. C., Lund-Katz, S., & Snow, J. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(02)00263-9 · Cited by 82 · cited 2×
“[67] P.”
Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis
Li, Y.-J., Pericak-Vance, M. A., Haines, J. L., Siddique, N., McKenna-Yasek, D., Hung, W.-Y., Sapp, P., Allen, C. I., Chen, W., Hosler, B., et al. (2004) · Neurogenetics · doi:10.1007/s10048-004-0193-0 · Cited by 77 · cited 1×
“Most striking results are the association with age at onset, with the APOE4 and APOE2 alleles, respectively, decreasing [270, 272] and increasing the age [270, 273], as well as the finding that APOE plasma levels (but not APOE genotype) were correlated with a faster rate of deterioration and shortened survival time [2…”
Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice
Krzywkowski, P., Ghribi, O., Gagné, J., Chabot, C., Kar, S., Rochford, J., Massicotte, G., & Poirier, J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00061-5 · Cited by 74 · cited 2×
“[172] P.”
Self-citationEarly and late onset Alzheimer’s disease patients have distinct patterns of white matter damage.
Canu, E., Frisoni, G. B., Agosta, F., Pievani, M., Bonetti, M., & Filippi, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.021 · Cited by 67 · cited 1×
“Among both AD groups, APOE4 positivity was associated with a greater parahippocampal white matter loss, supporting the contention that the APOE4 effect is restricted to parahippocampal white matter regions and not related to age of onset [208].”
Bojanowski, C. M., Shen, D., Chew, E. Y., Ning, B., Csaky, K. G., Green, W. R., Chan, C., & Tuo, J. (2006) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20233 · Cited by 62
Differential neurotrophic effects of apolipoprotein E in aged transgenic mice.
Veinbergs, I., Mallory, M., Mante, M., Rockenstein, E., Gilbert, J. R., & Masliah, E. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00243-8 · Cited by 46 · cited 2×
“[168] I.”
Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis
Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K., & Andersen, P. M. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.025 · Cited by 46
Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Cheng, D., Huang, R., Lanham, I. S., Cathcart, H. M., Howard, M., Corder, E. H., & Poduslo, S. E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024968 · Cited by 33 · cited 1×
“Furthermore, the fact that the APOE4 allele and LDLR genetic variations synergistically enhance the risk of developing AD by 11-fold [187] highlights the importance of both APOE synthesis and internalization in AD.”
Clément-Collin, V., Barbier, A., Dergunov, A. D., Visvikis, A., Siest, G., Desmadril, M., Takahashi, M., & Aggerbeck, L. P. (2006) · Biophysical Chemistry · doi:10.1016/j.bpc.2005.07.009 · Cited by 32 · cited 2×
“[68] V.”
Lai, M. K. P., Tsang, S. W. Y., Garcia-Alloza, M., Minger, S. L., Nicoll, J. A. R., Esiri, M. M., Wong, P. T.-H., Chen, C. P. L.-H., Ramírez, M. J., & Francis, P. T. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.016 · Cited by 29
Apolipoprotein E Mutants, Hyperlipidemia and Arteriosclerosis
Utermann, G. (1985) · Drugs Affecting Lipid Metabolism VIII · doi:10.1007/978-1-4613-2459-1_14 · Cited by 24 · cited 2×
“In accordance with their disparate protein stability, APOE2 is associated with the highest levels of APOE lipoprotein, whereas APOE4 is associated with the lowest in both the blood and brain [69–72].”
Cited by
Estrogens, Neuroinflammation, and Neurodegeneration
Villa, A., Vegeto, E., Poletti, A., & Maggi, A. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1007 · Cited by 423
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
“2,17 In particular, in several studies of APOE targeted replacement (TR) transgenic mice, mRNA expression levels did not differ among APOE variants, but protein levels were lowest in E4 and highest in E2 mice.”
La Cunza, N., Tan, L. X., Thamban, T., Germer, C. J., Rathnasamy, G., Toops, K. A., & Lakkaraju, A. (2021) · JCI Insight · doi:10.1172/jci.insight.142254 · Cited by 65
Beta-amyloid auto-antibodies are reduced in Alzheimer's disease
Qu, B.-X., Gong, Y., Moore, C., Fu, M., German, D. C., Chang, L.-Y., Rosenberg, R., & Diaz-Arrastia, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.06.017 · Cited by 47
Extracellular Proteolysis of Apolipoprotein E (apoE) by Secreted Serine Neuronal Protease
Tamboli, I. Y., Heo, D., & Rebeck, G. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093120 · Cited by 35
“ApoE exists in humans as three major isoforms (apoE2, apoE3, apoE4) that differ from each other at amino acid positions 112 and 158 [10,11].”
Background
Metadata
- Authors
- Leduc, V., Domenger, D., De Beaumont, L., Lalonde, D., Bélanger-Jasmin, S., & Poirier, J.
- Venue
- International Journal of Alzheimer’s Disease
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 2011
- Issue
- 1
- Pages
- 974361-974361
- ISSN
- 2090-0252 (ISSN-L)
- 2090-8024
- OpenAlex
- W1992465885
- Cited by
- 43
- References
- 105
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.